Skip to content

Changes in Abdominal Tissues Induced by Magnetic Device - CT Evaluation

Safety and Efficacy of Noninvasive Repetitive Pulse Magnetic Stimulation (rPMS) for Fat Disruption of the Abdomen

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03545646
Enrollment
0
Registered
2018-06-04
Start date
2017-12-15
Completion date
2019-06-15
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fat Burn

Keywords

Abdominal tissues

Brief summary

The study is a prospective multi-center open-label single-arm study. The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and four follow-up visits, 1 month, 3, 6 and 12 months after the final treatment. At the baseline visit, photographs of the abdomen will be taken. In addition, adipose/muscle layer thickness will be measured with the computed tomography and the subject's weight will be recorded. In addition, at the last therapy visit, subjects will receive Subject Satisfaction and Therapy Comfort Questionnaires to fill in. Safety measures will include documentation of adverse events (AE) including subject's experience of pain or discomfort after the procedure. Following each treatment administration and at the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment. Post-procedure evaluation (follow-up visits) will be conducted 1 month, 3, 6 and 12 months after the final treatment. Computed tomography and weight measure will be conducted at every follow-up visit. Also, subject's satisfaction will be noted. During the first (1 month), third (6 months) and last (12 months) follow-up visits, photographs of abdomen will be taken.

Interventions

The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.

Sponsors

BTL Industries Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult subjects of both genders with unwanted abdominal fat and expressing interest in treatment * Age ≥ 22 years * Voluntarily signed informed consent form * BMI ≤ 30 kg/m2

Exclusion criteria

* Cardiac pacemakers * Electronic implants * Pulmonary insufficiency * Metal implants * Drug pumps * Haemorrhagic conditions * Anticoagulation therapy * Heart disorders * Malignant tumor * Fever * Pregnancy * Breastfeeding * Following recent surgical procedures when muscle contraction may disrupt the healing process * Application over menstruating uterus * Application over areas of the skin which lack normal sensation * Scars, open lesions and wounds at the treatment area * Unrepaired abdominal hernia

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness of the device assessed through photography evaluation13 monthsPhotography evaluations with correct identification of pre-treatment images compared to post-treatment images.
Effectiveness of the device assessed through change in adipose/muscle layer thickness13 monthsChange in adipose/muscle layer thickness between pre-treatment and post-treatment based on computed tomography measurements.
Subject's satisfaction13 monthsThe 5-point Likert scale Subject Satisfaction Questionnaire will be used for an analysis of the subject's opinion of the therapy results. Subjects will be evaluating agreement with three different statements (concerning satisfaction with therapy results and appearance of abdominal area after therapy) by choosing an answer on a scale between 1 (Strongly disagree) and 5 (Strongly agree). Minimally 80% of the treated subjects should report the agreement with all three statements given in the questionnaire (answers Agree and Strongly agree) in order to claim subject's satisfaction with the therapy outcome.

Secondary

MeasureTime frameDescription
Safety of the device for non-invasive fat disruption13 monthsThe secondary objective of the study is to determine side effects and adverse events (AE) associated with the treatment of the abdominal area. The occurrence of adverse events will be followed throughout the whole study.
Therapy comfort3 monthsTherapy comfort will be noted at the last therapy visit. Subjects will be asked to evaluate the agreement with the statement concerning the conformity of the study treatment. Subjects will be evaluating the agreement by choosing an answer on a scale between 1 (Strongly disagree) and 5 (Strongly agree). Based on a given answers, the therapy comfort will be calculated.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026